Sernova Biotherapeutics Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Other Operating Expenses	10.31	15.02	31.66	40.5	24.75	6.94
Total Operating Expenses	10.31	15.02	31.66	40.5	24.75	6.94
Operating Income	-10.31	-15.02	-31.66	-40.5	-24.75	-6.94
Interest Income	0	0.03	0.39	1.5	0.58	0.07
Interest Expense	-1.68	-0.75	-0.59	-0.03	-0.12	-0.06
Other Non-Operating Income (Expense)	0.05	0.02	-0.32	0.04	-0.13	-0.04
Total Non-Operating Income (Expense)	-1.63	-0.71	-0.52	1.5	0.33	-0.03
Pretax Income	-11.94	-15.73	-32.19	-39	-24.42	-6.97
Provision for Income Taxes	-0.04	0.08	0.01	-	-	-
Net Income	-11.83	-15.74	-32.19	-39	-24.42	-6.97
Net Income to Common	-11.83	-15.74	-32.19	-39	-24.42	-6.97
Shares Outstanding (Basic)	336	328	307	303	274	246
Shares Outstanding (Diluted)	336	328	307	303	274	246
Shares Change (YoY)	5.30%	6.95%	1.19%	10.87%	11.43%	24.45%
EPS (Basic)	0.04	0.05	0.10	0.13	0.09	0.03
EPS (Diluted)	0.04	0.05	0.10	0.13	0.09	0.03
EPS Growth	-33.33%	-50.00%	-23.08%	44.44%	200.00%	-
Free Cash Flow	-5.5	-10.91	-18.9	-30.44	-14.75	-6.86
Free Cash Flow Per Share	-0.02	-0.03	-0.06	-0.10	-0.05	-0.03
EBITDA	-10.05	-14.68	-31.12	-40.06	-24.31	-6.67
EBIT	-10.31	-15.02	-31.66	-40.5	-24.75	-6.94
Effective Tax Rate	0.30%	-0.50%	-0.02%	0.00%	0.00%	0.00%